Positive News SentimentPositive NewsNASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News $0.62 +0.05 (+8.80%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$0.57▼$0.6250-Day Range$0.57▼$2.0652-Week Range$0.55▼$2.32Volume100,217 shsAverage Volume81,944 shsMarket Capitalization$15.30 millionP/E RatioN/ADividend YieldN/APrice Target$7.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TRACON Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,086.6% Upside$7.33 Price TargetShort InterestHealthy0.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$243,460 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.56) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.28 out of 5 starsMedical Sector256th out of 983 stocksBiological Products, Except Diagnostic Industry34th out of 164 stocks 3.5 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, TRACON Pharmaceuticals has a forecasted upside of 1,086.6% from its current price of $0.62.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.65% of the outstanding shares of TRACON Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRACON Pharmaceuticals has recently decreased by 38.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCON. Previous Next 2.6 News and Social Media Coverage News SentimentTRACON Pharmaceuticals has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TRACON Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $243,460.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by Institutions46.04% of the stock of TRACON Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($0.56) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About TRACON Pharmaceuticals (NASDAQ:TCON) StockTRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.Read More Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TCON Stock News HeadlinesMay 30, 2023 | finance.yahoo.comTRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual MeetingMay 25, 2023 | americanbankingnews.comHead to Head Comparison: Bavarian Nordic A/S (OTCMKTS:BVNRY) and TRACON Pharmaceuticals (NASDAQ:TCON)June 4, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 22, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.comMay 16, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Cut by HC WainwrightMay 14, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Price Target Lowered to $7.00 at Robert W. BairdMay 14, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) PT Lowered to $3.00May 12, 2023 | msn.comMaxim Group Maintains TRACON Pharmaceuticals (TCON) Buy RecommendationJune 4, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 12, 2023 | msn.comBaird Maintains TRACON Pharmaceuticals (TCON) Outperform RecommendationMay 12, 2023 | msn.comRecap: TRACON Pharma Q1 EarningsMay 11, 2023 | finance.yahoo.comQ1 2023 TRACON Pharmaceuticals Inc Earnings CallMay 10, 2023 | finance.yahoo.comTRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 10, 2023 | finance.yahoo.comTRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | americanbankingnews.comTRACON Pharmaceuticals (TCON) to Release Earnings on WednesdayMay 3, 2023 | finance.yahoo.comTRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023May 2, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated by Analysts at StockNews.comMay 1, 2023 | msn.comShort Volatility Alert: Tracon PharmaceuticalsApril 27, 2023 | americanbankingnews.comQ3 2023 EPS Estimates for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Boosted by HC WainwrightApril 25, 2023 | msn.comTracon Pharmaceuticals Plunges after Unfavorable Arbitration RulingApril 25, 2023 | msn.comTracon stock slumps ~15% after I-Mab gets favorable ruling in arbitrationApril 16, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Shares Cross Above 50 Day Moving Average of $1.69April 6, 2023 | finance.yahoo.comRunway Growth Finance Corp. Provides First Quarter 2023 Portfolio UpdateApril 3, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on TRACON Pharmaceuticals (TCON)March 31, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by StockNews.comMarch 14, 2023 | finance.yahoo.comTracon (TCON) Moves to Buy: Rationale Behind the UpgradeMarch 10, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on TRACON Pharmaceuticals (TCON)See More Headlines TCON Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCON Company Calendar Last Earnings3/08/2023Today6/04/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees19Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.33 High Stock Price Forecast$12.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+1,086.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-828.53% Return on Assets-178.45% Debt Debt-to-Equity RatioN/A Current Ratio0.50 Quick Ratio0.50 Sales & Book Value Annual Sales$350,000.00 Price / Sales43.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.46) per share Price / Book-1.34Miscellaneous Outstanding Shares24,746,000Free Float22,791,000Market Cap$15.29 million OptionableNot Optionable Beta1.36 Key ExecutivesCharles P. TheuerPresident, Chief Executive Officer & DirectorBonne J. AdamsChief Operating Officer & Executive VPScott B. BrownChief Financial OfficerJames L. FreddoChief Medical OfficerBrenda MarcziSenior Vice President-Regulatory AffairsKey CompetitorsFinch Therapeutics GroupNASDAQ:FNCHAceragenNASDAQ:ACGNAcorda TherapeuticsNASDAQ:ACOROrganovoNASDAQ:ONVOPeak BioNASDAQ:PKBOView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 41,874 shares on 5/16/2023Ownership: 0.174%Jane Street Group LLCBought 16,982 shares on 5/16/2023Ownership: 0.071%Renaissance Technologies LLCBought 33,551 shares on 5/12/2023Ownership: 0.708%Charles Schwab Investment Management Inc.Bought 22,638 shares on 5/12/2023Ownership: 0.095%Simplex Trading LLCBought 600 shares on 4/27/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TCON Stock - Frequently Asked Questions Should I buy or sell TRACON Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TCON shares. View TCON analyst ratings or view top-rated stocks. What is TRACON Pharmaceuticals' stock price forecast for 2023? 1 Wall Street analysts have issued 1-year target prices for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,086.6% from the stock's current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. How have TCON shares performed in 2023? TRACON Pharmaceuticals' stock was trading at $1.49 at the beginning of the year. Since then, TCON stock has decreased by 58.5% and is now trading at $0.6180. View the best growth stocks for 2023 here. Are investors shorting TRACON Pharmaceuticals? TRACON Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 161,000 shares, a decrease of 38.7% from the April 30th total of 262,500 shares. Based on an average daily trading volume, of 181,900 shares, the days-to-cover ratio is currently 0.9 days. View TRACON Pharmaceuticals' Short Interest. When is TRACON Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our TCON earnings forecast. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) released its quarterly earnings data on Wednesday, March, 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX). When did TRACON Pharmaceuticals IPO? (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. What is TRACON Pharmaceuticals' stock symbol? TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON." Who are TRACON Pharmaceuticals' major shareholders? TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.71%), Susquehanna International Group LLP (0.17%), Charles Schwab Investment Management Inc. (0.10%), Jane Street Group LLC (0.07%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown. View institutional ownership trends. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TRACON Pharmaceuticals' stock price today? One share of TCON stock can currently be purchased for approximately $0.62. How much money does TRACON Pharmaceuticals make? TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $15.29 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-29,140,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. How can I contact TRACON Pharmaceuticals? TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786. This page (NASDAQ:TCON) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.